Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-912 in advanced solid tumors
NCT06190886Phase 1Recruiting
- Sponsor
- Proviva Therapeutics
- Start
- Jun 2024
- Primary completion
- May 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTX-912 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Proviva Therapeutics. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Jun 2024; status: recruiting.
02
Drugs
PTX-912
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT06190886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190886.